Author

E. Verzoni

Institution: Fondazione IRCCS Istituto Nazionale dei Tumori

Observed institution: Fondazione IRCCS Istituto Nazionale dei Tumori

OpenAlex ID: A5159523850

Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy

2026 · D.Y.C. Heng, M. Schmidinger, et al. · Annals of Oncology

Works count: 1

Citation count:

H-index:

I10-index: